Trevi Therapeutics Inc

In a Stage 2 advancing trend with clear higher highs and higher lows, TRVI is undergoing a shallow pullback into the rising 9 and 20 EMAs, which have held as support. Despite overbought readings, volume and momentum behavior remain healthy, aligning with a speculative continuation approach. Medium-term bias is bullish, and current price behavior offers a tactical Buy Now opportunity on this pullback into the EMA support zone.

• ↑Pro forma cash of $334M extends runway to 2030 after $162M raise.
• ↑Phase II trials met primary endpoint, showing statistically significant cough reduction.
• ↓Q1 net loss $0.09/share underscores ongoing unprofitability.